Shopping Cart 0
Cart Subtotal
AED 0

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Toll Like Receptor 8 (CD288 or TLR8)-Pipeline Review, H2 2018

Summary

Toll Like Receptor 8 (CD288 or TLR8)-Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 5, 1, 5 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Musculoskeletal Disorders and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.

The latest report Toll Like Receptor 8-Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8)-Overview

Toll Like Receptor 8 (CD288 or TLR8)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8)-Companies Involved in Therapeutics Development

BioNTech AG

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Pfizer Inc

Vivelix Pharmaceuticals Ltd

Toll Like Receptor 8 (CD288 or TLR8)-Drug Profiles

854-A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUCPT-8m-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1508052-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + MEDI-9197-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6742-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9688-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-9200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INGMM-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-9197-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-262-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8)-Dormant Products

Toll Like Receptor 8 (CD288 or TLR8)-Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8)-Product Development Milestones

Featured News & Press Releases

Oct 11, 2018: Gilead to present data on Hepatitis B drug candidate GS-9688 at The Liver Meeting 2018

Jul 03, 2018: Recent Studies Unveil Clues to Using Immunotherapy as Cancer Treatment

Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors

Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting

Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus

Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy

Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer

Jul 16, 2014: Resolve Initiates Phase 2 Clinical Study in SLE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by BioNTech AG, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Dynavax Technologies Corp, H2 2018

Pipeline by Eisai Co Ltd, H2 2018

Pipeline by Galderma SA, H2 2018

Pipeline by Gilead Sciences Inc, H2 2018

Pipeline by Janus Biotherapeutics Inc, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Nektar Therapeutics, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Vivelix Pharmaceuticals Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Toll Like Receptor 8 (CD288 or TLR8) Therapeutic Products under Development, Key Players in Toll Like Receptor 8 (CD288 or TLR8) Therapeutics, Toll Like Receptor 8 (CD288 or TLR8) Pipeline Overview, Toll Like Receptor 8 (CD288 or TLR8) Pipeline, Toll Like Receptor 8 (CD288 or TLR8) Pipeline Assessment


Companies

BioNTech AG

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Pfizer Inc

Vivelix Pharmaceuticals Ltd

Toll Like Receptor 8 (CD288 or TLR8)-Pipeline Review, H2 2018

Summary

Toll Like Receptor 8 (CD288 or TLR8)-Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 5, 1, 5 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Musculoskeletal Disorders and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.

The latest report Toll Like Receptor 8-Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8)-Overview

Toll Like Receptor 8 (CD288 or TLR8)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8)-Companies Involved in Therapeutics Development

BioNTech AG

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Pfizer Inc

Vivelix Pharmaceuticals Ltd

Toll Like Receptor 8 (CD288 or TLR8)-Drug Profiles

854-A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUCPT-8m-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1508052-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + MEDI-9197-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6742-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9688-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-9200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INGMM-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-9197-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-262-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8)-Dormant Products

Toll Like Receptor 8 (CD288 or TLR8)-Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8)-Product Development Milestones

Featured News & Press Releases

Oct 11, 2018: Gilead to present data on Hepatitis B drug candidate GS-9688 at The Liver Meeting 2018

Jul 03, 2018: Recent Studies Unveil Clues to Using Immunotherapy as Cancer Treatment

Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors

Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting

Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus

Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy

Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer

Jul 16, 2014: Resolve Initiates Phase 2 Clinical Study in SLE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by BioNTech AG, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Dynavax Technologies Corp, H2 2018

Pipeline by Eisai Co Ltd, H2 2018

Pipeline by Galderma SA, H2 2018

Pipeline by Gilead Sciences Inc, H2 2018

Pipeline by Janus Biotherapeutics Inc, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Nektar Therapeutics, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Vivelix Pharmaceuticals Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Toll Like Receptor 8 (CD288 or TLR8) Therapeutic Products under Development, Key Players in Toll Like Receptor 8 (CD288 or TLR8) Therapeutics, Toll Like Receptor 8 (CD288 or TLR8) Pipeline Overview, Toll Like Receptor 8 (CD288 or TLR8) Pipeline, Toll Like Receptor 8 (CD288 or TLR8) Pipeline Assessment


Companies

BioNTech AG

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Pfizer Inc

Vivelix Pharmaceuticals Ltd